The Incheon Free Economic Zone Authority announced on the 2nd that it has approved the building permit for Seoul Asan Cheongna Hospital in the Cheongna Medical Complex Town.
Seoul Asan Cheongna Hospital is planned to open in 2029 and will be constructed on a 97,459㎡ site in MF1 Block of Cheongna International City. The hospital will have 2 basement floors and 19 above-ground floors, with a total floor area of 165,899㎡. It will include specialized centers for severe patients such as a cancer center, and centers for cardiology, gastroenterology, spine, and joints, with a total of 800 beds planned.
With the building permit now approved, the necessary approval procedures for construction, including the underground safety impact assessment, will be promptly completed. Construction is scheduled to begin in the first half of this year, with completion and opening targeted for 2029.
Seoul Asan Hospital recently ranked 1st in South Korea and 22nd worldwide in the '2024 World's Best Hospitals' survey conducted by the U.S. news magazine Newsweek. Additionally, in the world rankings by specialty, four fields?cancer, gastroenterology, endocrinology, and urology?entered the top 5 globally.
Meanwhile, the Cheongna Medical Complex Town will include Seoul Asan Cheongna Hospital along with research institutes from the Korea Advanced Institute of Science and Technology (KAIST) and Harvard Medical School (MGH), a startup education facility called Life Science Park, Meditel, and senior healthcare facilities. These facilities are currently undergoing building permit processes individually, and Meditel, which will be directly operated by Seoul Asan Cheongna Hospital, is expected to receive its building permit soon.
An official from the Incheon Free Economic Zone Authority stated, "Seoul Asan Cheongna Hospital will dramatically improve the quality of medical services and become a new central axis for research and startups. We will provide maximum support for the prompt commencement of construction."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.


